Broadening anticancer spectrum by preprocessing and treatment of T- lymphocytes expressed FcγRI and monoclonal antibodies for refractory cancers

BackgroundChimeric antigen receptor T (CAR-T) cell therapies have achieved remarkable success in the treatment of hematological tumors. However, given the distinct features of solid tumors, particularly heterogeneity, metabolic aggressiveness, and fewer immune cells in tumor microenvironment (TME),...

Descripció completa

Dades bibliogràfiques

Autors principals:	Lei Tang, Qinyi Sun, Mengyuan Li, Xiaoxiao Yu, Jinguo Meng, Yun Zhang, Yuxiao Ma, Aizhong Zeng, Zhuolan Li, Yuanyuan Liu, Xinyu Xu, Wei Guo
Format:	Artigo
Idioma:	Inglês
Publicat:	Frontiers Media S.A. 2024-06-01
Col·lecció:	Frontiers in Immunology
Matèries:	CAR-T monoclonal antibodies FcγRI ADCC solid tumors
Accés en línia:	https://www.frontiersin.org/articles/10.3389/fimmu.2024.1400177/full
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!